---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-036612"
form_type: "8-K"
ticker: null
cik: "0001017491"
company_name: "SEELOS THERAPEUTICS, INC."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T16:06:57.009395+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Seelos Therapeutics adopts amended bylaws for universal proxy rules and enhanced disclosure

## Summary
- Board approved Amended and Restated Bylaws effective March 23, 2023.
- Amendments require compliance with SEC Rule 14a-19 universal proxy rules, including notice and solicitation requirements.
- Enhanced disclosure requirements for director nominations and stockholder proposals; background info on nominating stockholders and nominees required.
- Stockholders cannot nominate more candidates than board seats; Board may require nominee interviews.
- Stockholders soliciting proxies must use non-white proxy card; white reserved for Board. Remote meetings allowed.

## SEC filing metadata
- accession: 0001104659-23-036612
- form_type: 8-K
- cik: 0001017491
- company_name: SEELOS THERAPEUTICS, INC.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1017491/000110465923036612/0001104659-23-036612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1017491/000110465923036612/tm2310391d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-036612
- JSON: https://secwatch.observer/filing/0001104659-23-036612.json
- Plain text: https://secwatch.observer/filing/0001104659-23-036612.txt

## Key facts
- Governance Changes
  SEELOS THERAPEUTICS, INC.: Amended and restated bylaws to address universal proxy rules and enhance disclosure requirements for director nominations and stockholder proposals (effective 2023-03-23).
  - Change: bylaw amendment
  - Effective: 2023-03-23
  source text: On March 23, 2023, the Board of Directors (the “Board”) of Seelos Therapeutics, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of such date. The amendments effected by the Amended and Restated Bylaws address the universal proxy rules promulgated by the U.S. Securities and Exchange Commission, as set forth in Rule 14a-19 of the Securities Exchange Act of 1934, as amended (the “1934 Act”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1017491/000110465923036612/0001104659-23-036612-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.